Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials

Rechallenge with anti-EGFR drugs represents a promising strategy in refractory <i>RAS</i>/<i>BRAF</i> wild-type (WT) metastatic colorectal cancer (mCRC). We performed the pooled analysis of the CAVE and VELO studies to evaluate the percentage of patients with WT circulating t...

Full description

Bibliographic Details
Main Authors: Davide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, Alessandra Di Liello, Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Maria Giulia Zampino, Nicola Fazio, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
anti-EGFR drugs
rechallenge therapy
liquid biopsy
metastatic colorectal cancer
Online Access:https://www.mdpi.com/2072-6694/15/7/2117

Internet

https://www.mdpi.com/2072-6694/15/7/2117

Similar Items